Aetion and HealthVerity have launched a new set of tools for biopharma companies and regulators looking to assess new COVID-19 treatments, according to a MobiHealthNews report.
Aetion CEO Carolyn Magill in a statement said the “stakes are incredibly high” as the industry works to develop COVID-19 treatments.
“Our offerings use HealthVerity’s comprehensive, real-time data to obtain decision-ready insights that can help meet the need for accelerated approvals and access, while maintaining our high bar for evidence to support critical safety and effectiveness determinations,” she said.
To read the full report on MobiHealthNews, click here.
